查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
病理學人工智慧的全球市場：按產品、按神經網路、按功能、按使用案例、按最終用戶、按地區 - 預測到 2029 年
市場調查報告書
商品編碼
1596803

病理學人工智慧的全球市場：按產品、按神經網路、按功能、按使用案例、按最終用戶、按地區 - 預測到 2029 年

AI in Pathology Market by Neural Network, Function, Use Case, End User, & Region - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 292 Pages | 訂單完成後即時交付

價格

全球病理學人工智慧市場規模預計將從 2024 年的 8,280 萬美元增至 2029 年的 1.698 億美元，預測期內複合年成長率高達 15.4%。

病理學人工智慧是指醫療保健產業的一個領域，包括專門為病理學設計的人工智慧（AI）的開發、部署和利用。可以使用這些人工智慧模型來分析臨床資料、基因組資訊和疾病進展。這些人工智慧模型可以幫助制定個人化治療計劃、識別高風險患者並最佳化醫療資源分配。 AI 透過使用先進的 AI 演算法、電腦視覺和機器學習，幫助病理學家提取相關資訊並分析影像。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
考慮單位 百萬/十億（美元）
按細分市場 透過提供、透過神經網路、透過功能、透過使用案例、透過最終用戶、透過區域
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲

2023年，藥物發現領域佔病理學市場人工智慧的最大佔有率。其關鍵促進因素是對高效且具有成本效益的藥物的高需求，而病理學領域的人工智慧可以透過自動化資料分析和更快地識別潛在藥物來幫助改善藥物發現過程，因為它有助於加速。此外，用於高通量篩檢的成像技術的進步以及人工智慧在非法藥物毒理學測試中的使用也正在推動這個市場。而且，傳統方法非常耗時且成本高昂，因此減少時間和成本起著非常重要的作用。在病理學中引入人工智慧可以更快地獲得洞察和決策，幫助簡化流程。結果，該過程變得更加高效和具有成本效益，所有這些因素共同成為該市場成長的催化劑。

預計製藥和生物製藥公司領域將在預測期內呈現最高成長率。製藥公司和人工智慧供應商之間日益加強的合作正在推動人工智慧的快速採用，各公司也在人工智慧工具上進行了大量投資，以保持在藥物開發和創新方面的競爭力。人工智慧透過分析大型資料集、識別組織樣本中的模式並預測治療反應，幫助快速追蹤和簡化藥物發現過程，減少時間消耗並使其更具成本效益，從而加快創新速度。生物製藥公司依賴基於人工智慧的數位病理學，因為人工智慧驅動的病理學透過提供對個人投資組合的詳細見解來支持個人化醫療的發展。

該報告研究了病理學市場中的全球人工智慧，包括產品、神經網路、功能、使用案例、最終用戶、區域和參與市場的公司概況的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 影響客戶業務的趨勢/干擾
  • 產業動態
  • 生態系分析
  • 價值鏈分析
  • 技術分析
  • 監管分析
  • 價格分析
  • 波特五力分析
  • 專利分析
  • 主要相關人員和採購標準
  • 最終用戶分析
  • 2024-2025年重大會議和活動
  • 案例研究分析
  • 投資金籌措場景
  • 病理市場中的人工智慧：經營模式
  • 人工智慧/生成人工智慧對病理市場人工智慧的影響
  • 貿易分析

第6章病理學人工智慧市場（依產品分類）

  • 介紹
  • 端對端解決方案
  • 利基點解決方案
  • 科技
  • 硬體
  • 顯微鏡
  • 掃描器
  • 儲存系統

第7章病理學人工智慧市場，作者：神經網路

  • 介紹
  • 卷積類神經網路(CNNS)
  • 生成對抗網路（GANS）
  • 循環神經網路 (RNNS)
  • 其他

第 8 章病理學人工智慧市場（按功能）

  • 介紹
  • 影像分析
  • 診斷
  • 工作流程管理
  • 資料管理
  • 預測分析
  • CDSS
  • 自動產生報告
  • 品質保證工具

第 9 章病理學人工智慧市場（按使用案例）

  • 介紹
  • 藥物發現
  • 疾病診斷與預後
  • 臨床工作流程
  • 培訓和教育

第 10 章病理學人工智慧市場（按最終用戶）

  • 介紹
  • 製藥和生物製藥公司
  • 醫院和實驗室
  • 學術研究所

第11章病理學人工智慧市場（按地區）

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第12章競爭格局

  • 介紹
  • 主要參與企業的策略/秘密
  • 2019-2023年收益分析
  • 2023 年市場佔有率分析
  • 企業評估矩陣：主要參與企業，2023
  • 企業評估矩陣：Start-Ups/小型企業，2023 年
  • 公司評價及財務指標
  • 競爭場景

第13章 公司簡介

  • 主要參與企業
    • KONINKLIJKE PHILIPS NV
    • F. HOFFMANN-LA ROCHE LTD.
    • HOLOGIC, INC.
    • AKOYA BIOSCIENCES, INC.
    • AIFORIA TECHNOLOGIES PLC
    • INDICA LABS INC.
    • OPTRASCAN
    • IBEX MEDICAL ANALYTICS LTD.
    • MINDPEAK GMBH
    • TRIBUN HEALTH
    • TECHCYTE, INC.
    • DEEP BIO INC.
    • LUMEA INC.
    • VISIOPHARM
    • AETHERAI
    • AIOSYN
    • PAIGE AI, INC.
    • PROSCIA, INC.
    • PATHAI, INC.
    • TEMPUS LABS, INC.
  • 其他公司
    • KONFOONG BIOINFORMATION TECH CO., LTD.
    • DOMORE DIAGNOSTICS AS
    • VERILY LIFE SCIENCES, LLC
    • DEEPPATH
    • 4D PATH INC.

第14章附錄

Product Code: HIT 8721

The global AI in Pathology market is expected to reach USD 169.8 million by 2029 from USD 82.8 million in 2024 at a high CAGR of 15.4% during the forecast period. AI in pathology refers to the healthcare industry's sector which comprises of development, deployment, and utilization of Artificial Intelligence (AI) designed for pathology applications specifically. Clinical data, genomic information, and disease progression can be analysed by using these AI models. These AI models assist in personalized treatment planning, identifying high-risk patients, and optimizing healthcare resource allocation. The AI helps and assists pathologists in extracting relevant information and analyzing images with the use of advanced AI algorithms, computer vision, and machine learning.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredMillion/Billion (USD)
SegmentsBy Offering, Neural Networks, Functions, Use Case, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East and Africa

"The drug discovery segment accounted for the largest share in 2023, by use case."

In 2023, the drug discovery segment held the largest share of the AI in pathology market. The major factor behind this is the high demand for efficient and cost-effective drugs, as AI in pathology helps in accelerating the drug discovery process by automating the data analytics and identifying potential drug faster. In addition, the advancements in high throughput screenings imaging technologies and utilization of AI in toxicology testing for illicit drugs also act as a driving force for this market. Furthermore, the reduced time and costs play a very vital role as traditional methods are very time consuming and expensive as well, the introduction of AI in pathology helps in streamlining the process by enabling faster insights and decision making. Which in tun makes the process more efficient and cost effective, these all factors combined act as a catalyst for the growth of this market.

"Pharmaceutical and biopharmaceutical companies is the fastest growing end-user segment in the AI in pathology market."

The pharmaceutical and biopharmaceutical companies segment is projected to witness the highest growth rate during the forecast period. The growing collaboration between pharmaceutical companies and AI providers fuels rapid adoption of AI, also the companies are heavily investing in AI tools to stay competitive in drug development and innovation. As AI helps in fast tracking and streamlining the processes for drug discovery by analysing large datasets, identifying patterns in tissue samples, and predicting treatment responses, which reduces the time consumption and makes it cost effective, leading to faster innovations. The biopharmaceutical companies rely on AI-based digital pathology for majorly development of individualized medicine, as AI powered pathology aids the development of personalised medicine by providing detailed insights into individual portfolio.

"North America accounted for the largest share in 2023, in AI in pathology market."

In 2023, the North American region held the largest market share in the AI in pathology market due to several factors. The first and foremost being the high adoption of AI technology and strong investment in research and development driving the market growth. For instance, companies like Koninklijke Philips N.V. in 2023, invested nearly USD 895 million in R&D for diagnosis and treatment. On the other hand, the advanced healthcare infrastructre plays a very vital role in this market as there's a need of high tech machinery such as advanced microscopes and scanners. Morover, the large patient pool and data availability contributes in creating a large database, which can be further used to train the AI for greater accuracy and efficiency. This increasing focus on technoology, patient safety, and quality improvement, combined with technological advancements in medical devices, continues to drive the adoption of AI in pathology market in North America.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 55%, Tier 2: 25%, and Tier 3: 20%
  • By Designation - C-level: 50%, Director-level: 30%, and Others: 20%
  • By Region - North America: 40%, Europe: 35%, Asia Pacific: 20%, RoW: 5%

Key Players in the AI in pathology Market

The key players functioning in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAI (Taiwan), Aiosyn (Netherlands), Paige AI, Inc. (US), Proscia Inc. (US), PathAI, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).

Research Coverage:

The report analyses the AI in pathology market. It aims to estimate the market size and future growth potential of various market segments based on by offerings, neural networks, use-case, end-user, by functions and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Analysis of key drivers (Rising strategic collaborations among market players, integration of AI in multiplex imaging, Rising cases of misdiagnoses, AI-augmented telepathology broadening access to specialized pathology services, and technological advancements in deep learning), restraints (High cost of digital pathology systems, the scarcity of AI expertise and unclear regulatory guidelines for medical software, and lack of interoperability with legacy systems), opportunities (Growing demand for personalized medicine, integration of multi-omics data, and predictive analytics for disease Progression) challenges (Lack of sufficient data to train AI algorithms, data privacy, and ethical concerns, interpretability of AI models) influencing the growth of the AI in pathology market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market.
  • Market Development: Comprehensive information on the lucrative emerging markets, offering, neural networks, functions, use-case, end-user, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in pathology market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in pathology market like Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 MARKET STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 STUDY ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS
    • 2.5.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.5.2 SCOPE-RELATED LIMITATIONS
  • 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 AI IN PATHOLOGY MARKET OVERVIEW
  • 4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX
  • 4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER & COUNTRY
  • 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Development of CNNs and advanced AI models
      • 5.2.1.2 Integration of AI into multiplex imaging
      • 5.2.1.3 Increasing cases of misdiagnoses in patients
      • 5.2.1.4 Benefits of AI-augmented telepathology
      • 5.2.1.5 Advancements in deep learning & image processing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of digital pathology systems
      • 5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software
      • 5.2.2.3 Inadequate interoperability issues with legacy systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing demand for personalized medicine
      • 5.2.3.2 Integration of multi-omics data
      • 5.2.3.3 Predictive analytics for disease progression
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Insufficient data for AI algorithms
      • 5.2.4.2 Data privacy & ethical concerns
      • 5.2.4.3 Challenges associated with interpretability of AI models
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 INDUSTRY TRENDS
    • 5.4.1 EVOLUTION OF AI IN PATHOLOGY
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 TECHNOLOGY ANALYSIS
    • 5.7.1 KEY TECHNOLOGIES
      • 5.7.1.1 Machine learning and artificial intelligence
      • 5.7.1.2 Computer vision
    • 5.7.2 COMPLEMENTARY TECHNOLOGIES
      • 5.7.2.1 Cloud computing
    • 5.7.3 ADJACENT TECHNOLOGIES
      • 5.7.3.1 Telepathology
  • 5.8 REGULATORY ANALYSIS
    • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.8.2 REGULATORY LANDSCAPE
      • 5.8.2.1 North America
        • 5.8.2.1.1 US
        • 5.8.2.1.2 Canada
      • 5.8.2.2 Europe
      • 5.8.2.3 Asia Pacific
        • 5.8.2.3.1 Japan
        • 5.8.2.3.2 China
  • 5.9 PRICING ANALYSIS
    • 5.9.1 INDICATIVE PRICING ANALYSIS, BY OFFERING
    • 5.9.2 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT OF NEW ENTRANTS
    • 5.10.2 THREAT OF SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF SUPPLIERS
    • 5.10.4 BARGAINING POWER OF BUYERS
    • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11 PATENT ANALYSIS
    • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS
    • 5.11.2 JURISDICTION & TOP APPLICANT ANALYSIS
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.12.2 BUYING CRITERIA
  • 5.13 END-USER ANALYSIS
    • 5.13.1 UNMET NEEDS OF END USERS
    • 5.13.2 END-USER EXPECTATIONS
  • 5.14 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 CASE STUDY 1: PATHAI USES PYTORCH TO IMPROVE PATIENT OUTCOMES WITH AI-POWERED PATHOLOGY
    • 5.15.2 CASE STUDY 2: COMBATING CERVICAL CANCER WITH AI
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 AI IN PATHOLOGY MARKET: BUSINESS MODELS
  • 5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET
    • 5.18.1 KEY USE CASES
    • 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
      • 5.18.2.1 Case Study: Accelerated biomarker discovery and clinical trial optimization
    • 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 5.18.3.1 Drug discovery & development market
      • 5.18.3.2 Medical imaging & diagnostics market
    • 5.18.4 USERS READINESS AND IMPACT ASSESSMENT
      • 5.18.4.1 User readiness
        • 5.18.4.1.1 Pharmaceutical companies
        • 5.18.4.1.2 Biopharmaceutical companies
      • 5.18.4.2 Impact assessment
        • 5.18.4.2.1 User A: Pharmaceutical companies
          • 5.18.4.2.1.1 Implementation
          • 5.18.4.2.1.2 Impact
        • 5.18.4.2.2 User B: Biopharmaceutical companies
          • 5.18.4.2.2.1 Implementation
          • 5.18.4.2.2.2 Impact
  • 5.19 TRADE ANALYSIS
    • 5.19.1 IMPORT DATA
    • 5.19.2 EXPORT DATA

6 AI IN PATHOLOGY MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 END-TO-END SOLUTIONS
    • 6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET
  • 6.3 NICHE POINT SOLUTIONS
    • 6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET
  • 6.4 TECHNOLOGY
    • 6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL UPTAKE
  • 6.5 HARDWARE
  • 6.6 MICROSCOPES
    • 6.6.1 AUTOMATED ANALYSIS OF TISSUE SAMPLES FOR EFFECTIVE CONCLUSIONS TO FUEL UPTAKE
  • 6.7 SCANNERS
    • 6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND
  • 6.8 STORAGE SYSTEMS
    • 6.8.1 ABILITY TO PROVIDE STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH

7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK

  • 7.1 INTRODUCTION
  • 7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS)
    • 7.2.1 ABILITY TO PROVIDE HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET
  • 7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS)
    • 7.3.1 DESIGNED FOR GENERATION OF ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET
  • 7.4 RECURRENT NEURAL NETWORKS (RNNS)
    • 7.4.1 ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL UPTAKE
  • 7.5 OTHER NEURAL NETWORKS

8 AI IN PATHOLOGY MARKET, BY FUNCTION

  • 8.1 INTRODUCTION
  • 8.2 IMAGE ANALYSIS
    • 8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE
  • 8.3 DIAGNOSTICS
    • 8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET
  • 8.4 WORKFLOW MANAGEMENT
    • 8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE
  • 8.5 DATA MANAGEMENT
    • 8.5.1 ADVANCEMENTS IN DATA INTEGRATION & PROCESSING TO BOOST DEMAND
  • 8.6 PREDICTIVE ANALYTICS
    • 8.6.1 GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
  • 8.7 CDSS
    • 8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET
  • 8.8 AUTOMATED REPORT GENERATION
    • 8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET
  • 8.9 QUALITY ASSURANCE TOOLS
    • 8.9.1 RISING REGULATORY DEMANDS TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS

9 AI IN PATHOLOGY MARKET, BY USE CASE

  • 9.1 INTRODUCTION
  • 9.2 DRUG DISCOVERY
    • 9.2.1 TARGET IDENTIFICATION & SELECTION
      • 9.2.1.1 Analysis of molecular & histological data for biomarker discovery to fuel market
    • 9.2.2 TARGET VALIDATION
      • 9.2.2.1 Increasing demand for precision medicine to drive market
    • 9.2.3 HIT IDENTIFICATION & PRIORITIZATION
      • 9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake
    • 9.2.4 HIT-TO-LEAD IDENTIFICATION
      • 9.2.4.1 Advancements in ML to support market growth
    • 9.2.5 LEAD OPTIMIZATION
      • 9.2.5.1 Growing focus on therapeutic efficacy to propel market
    • 9.2.6 CANDIDATE SELECTION & VALIDATION
      • 9.2.6.1 Critical requirement for regulatory approvals to drive market
  • 9.3 DISEASE DIAGNOSIS & PROGNOSIS
    • 9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET
  • 9.4 CLINICAL WORKFLOW
    • 9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET
  • 9.5 TRAINING & EDUCATION
    • 9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH

10 AI IN PATHOLOGY MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET
  • 10.3 HOSPITALS & REFERENCE LABORATORIES
    • 10.3.1 INCREASING UPTAKE OF INFECTIOUS DISEASE DIAGNOSIS TO DRIVE MARKET
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    • 10.4.1 INCREASING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH

11 AI IN PATHOLOGY MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 UK
      • 11.3.2.1 Increasing focus on drug discovery & development to boost demand
    • 11.3.3 GERMANY
      • 11.3.3.1 Availability of funding for AI initiatives to fuel uptake
    • 11.3.4 FRANCE
      • 11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake
    • 11.3.5 ITALY
      • 11.3.5.1 Digital transformation and innovation in healthcare to support market growth
    • 11.3.6 SPAIN
      • 11.3.6.1 Workforce shortages to fuel market
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Increasing incidence of infectious & chronic diseases to fuel uptake
    • 11.4.3 JAPAN
      • 11.4.3.1 Advanced healthcare infrastructure to propel market
    • 11.4.4 INDIA
      • 11.4.4.1 Growing focus on healthcare digitization to boost demand
    • 11.4.5 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Strategic investments for AI adoption to support market growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Growth in pharmaceutical R&D to drive market
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Increasing investments in expansion of technological expertise to support market growth
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET
  • 12.3 REVENUE ANALYSIS, 2019-2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Offering footprint
      • 12.5.5.3 Use-case footprint
      • 12.5.5.4 End-user footprint
      • 12.5.5.5 Region footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS /SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 COMPANY VALUATION
    • 12.7.2 FINANCIAL METRICS
    • 12.7.3 BRAND/SOFTWARE COMPARISON ANALYSIS
  • 12.8 COMPETITIVE SCENARIO
    • 12.8.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
    • 12.8.2 DEALS
    • 12.8.3 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 KONINKLIJKE PHILIPS N.V.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products/Services offered
      • 13.1.1.3 MnM view
        • 13.1.1.3.1 Key strengths
        • 13.1.1.3.2 Strategic choices
        • 13.1.1.3.3 Weaknesses & competitive threats
    • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products/Services offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product/Service launches
        • 13.1.2.3.2 Deals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Key strengths
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 HOLOGIC, INC.
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products/Services offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product/Service approvals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Key strengths
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 AKOYA BIOSCIENCES, INC.
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products/Services offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Key strengths
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 AIFORIA TECHNOLOGIES PLC
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products/Services offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Deals
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Key strengths
        • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.3 Weaknesses & competitive threats
    • 13.1.6 INDICA LABS INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products/Services offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product/Service launches & approvals
        • 13.1.6.3.2 Deals
        • 13.1.6.3.3 Expansions
    • 13.1.7 OPTRASCAN
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products/Services offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Other developments
    • 13.1.8 IBEX MEDICAL ANALYTICS LTD.
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products/Services offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Product/Service launches & approvals
        • 13.1.8.3.2 Deals
    • 13.1.9 MINDPEAK GMBH
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products/Services offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product/Service approvals
        • 13.1.9.3.2 Deals
        • 13.1.9.3.3 Other developments
    • 13.1.10 TRIBUN HEALTH
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products/Services offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Deals
    • 13.1.11 TECHCYTE, INC.
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products/services offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product/Service launches
        • 13.1.11.3.2 Deals
        • 13.1.11.3.3 Other developments
    • 13.1.12 DEEP BIO INC.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products/Services offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Deals
    • 13.1.13 LUMEA INC.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products/Services offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Deals
    • 13.1.14 VISIOPHARM
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products/Services offered
        • 13.1.14.2.1 Recent developments
        • 13.1.14.2.2 Product/Service launches
        • 13.1.14.2.3 Expansions
    • 13.1.15 AETHERAI
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products/Services offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Deals
    • 13.1.16 AIOSYN
      • 13.1.16.1 Business overview
      • 13.1.16.2 Product/Services offered
        • 13.1.16.2.1 Product/Service launches
      • 13.1.16.3 Recent developments
        • 13.1.16.3.1 Deals
      • 13.1.16.4 Recent developments
        • 13.1.16.4.1 Other developments
    • 13.1.17 PAIGE AI, INC.
      • 13.1.17.1 Business overview
      • 13.1.17.2 Products/Services offered
      • 13.1.17.3 Recent developments
        • 13.1.17.3.1 Product/Service launches & approvals
        • 13.1.17.3.2 Deals
        • 13.1.17.3.3 Other developments
    • 13.1.18 PROSCIA, INC.
      • 13.1.18.1 Business overview
      • 13.1.18.2 Products/Services offered
      • 13.1.18.3 Recent developments
        • 13.1.18.3.1 Product/Service launches & enhancements
        • 13.1.18.3.2 Deals
        • 13.1.18.3.3 Other developments
    • 13.1.19 PATHAI, INC.
      • 13.1.19.1 Business overview
      • 13.1.19.2 Products/Services offered
      • 13.1.19.3 Recent developments
        • 13.1.19.3.1 Product/Service launches & approvals
        • 13.1.19.3.2 Deals
    • 13.1.20 TEMPUS LABS, INC.
      • 13.1.20.1 Business overview
      • 13.1.20.2 Products/Services offered
      • 13.1.20.3 Recent developments
        • 13.1.20.3.1 Product/Service launches
  • 13.2 OTHER PLAYERS
    • 13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD.
    • 13.2.2 DOMORE DIAGNOSTICS AS
    • 13.2.3 VERILY LIFE SCIENCES, LLC
    • 13.2.4 DEEPPATH
    • 13.2.5 4D PATH INC.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 2 STUDY ASSUMPTION ANALYSIS
  • TABLE 3 RISK ASSESSMENT ANALYSIS
  • TABLE 4 AI IN PATHOLOGY MARKET: ROLE IN ECOSYSTEM
  • TABLE 5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES
  • TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 12 INDICATIVE PRICING ANALYSIS, BY OFFERING
  • TABLE 13 AI IN PATHOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS (%)
  • TABLE 15 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS
  • TABLE 16 UNMET NEEDS FOR AI IN PATHOLOGY MARKET
  • TABLE 17 END-USER EXPECTATIONS FOR AI IN PATHOLOGY MARKET
  • TABLE 18 AI IN PATHOLOGY MARKET: LIST OF CONFERENCES AND EVENTS
  • TABLE 19 IMPORT DATA FOR HS CODE 9011, BY COUNTRY, 2020-2022 (USD THOUSAND)
  • TABLE 20 EXPORT DATA FOR HS CODE 9011, BY COUNTRY, 2020-2022 (USD THOUSAND)
  • TABLE 21 AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 22 AI IN PATHOLOGY MARKET FOR OFFERING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 23 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 AI IN PATHOLOGY MARKET FOR NICHE-POINT SOLUTIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 25 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 26 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 27 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 AI IN PATHOLOGY MARKET, BY NEURAL NETWORKS, 2022-2029 (USD MILLION)
  • TABLE 32 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 37 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 46 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY
  • TABLE 47 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 48 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 59 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 AI IN PATHOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 63 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 69 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 70 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 71 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 72 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 73 US: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 74 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 75 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 79 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 85 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 86 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 87 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 88 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 89 UK: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 90 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 91 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 95 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 96 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 100 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 101 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 105 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 106 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 110 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 111 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 121 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 122 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 126 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
  • TABLE 127 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 128 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 132 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 133 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 137 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 138 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 142 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 148 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 149 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 153 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 154 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 158 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 159 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 163 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 164 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 169 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 170 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 174 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 175 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2022-2029 (USD MILLION)
  • TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE, 2022-2029 (USD MILLION)
  • TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 179 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
  • TABLE 180 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 181 OFFERING FOOTPRINT ANALYSIS
  • TABLE 182 USE-CASE FOOTPRINT ANALYSIS
  • TABLE 183 END-USER FOOTPRINT ANALYSIS
  • TABLE 184 REGION FOOTPRINT ANALYSIS
  • TABLE 185 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 186 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 187 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 188 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 189 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, 2021-2024
  • TABLE 190 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 191 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED
  • TABLE 192 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 193 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 194 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 195 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 196 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 197 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 198 HOLOGIC, INC.: PRODUCT/SERVICE APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 199 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 200 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED
  • TABLE 201 AKOYA BIOSCIENCES INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 202 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW
  • TABLE 203 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED
  • TABLE 204 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 205 INDICA LABS INC.: COMPANY OVERVIEW
  • TABLE 206 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 207 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 208 INDICA LABS INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 209 INDICA LABS INC.: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 210 OPTRASCAN: COMPANY OVERVIEW
  • TABLE 211 OPTRASCAN: PRODUCTS/SERVICES OFFERED
  • TABLE 212 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 213 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW
  • TABLE 214 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 215 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES/APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 216 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 217 MINDPEAK GMBH: COMPANY OVERVIEW
  • TABLE 218 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED
  • TABLE 219 MINDPEAK GMBH: PRODUCT/SERVICE APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 220 MINDPEAK GMBH: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 221 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 222 TRIBUN HEALTH: COMPANY OVERVIEW
  • TABLE 223 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED
  • TABLE 224 TRIBUN HEALTH: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 225 TECHCYTE, INC.: COMPANY OVERVIEW
  • TABLE 226 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 227 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 228 TECHCYTE, INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 229 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 230 DEEP BIO INC.: COMPANY OVERVIEW
  • TABLE 231 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 232 DEEP BIO INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 233 LUMEA INC.: COMPANY OVERVIEW
  • TABLE 234 LUMEA INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 235 LUMEA INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 236 VISIOPHARM: COMPANY OVERVIEW
  • TABLE 237 VISIOPHARM: PRODUCTS/SERVICES OFFERED
  • TABLE 238 VISIOPHARM: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 239 VISIOPHARM: EXPANSIONS, JANUARY 2021-OCTOBER 2024
  • TABLE 240 AETHERAI: COMPANY OVERVIEW
  • TABLE 241 AETHERAI: PRODUCTS/SERVICES OFFERED
  • TABLE 242 AETHERAI: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 243 AIOSYN: COMPANY OVERVIEW
  • TABLE 244 AIOSYN: PRODUCTS/SERVICES OFFERED
  • TABLE 245 AIOSYN: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 246 AIOSYN: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 247 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 248 PAIGE AI, INC.: COMPANY OVERVIEW
  • TABLE 249 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 250 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 251 PAIGE AI, INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 252 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 253 PROSCIA, INC.: COMPANY OVERVIEW
  • TABLE 254 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 255 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 256 PROSCIA, INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 257 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
  • TABLE 258 PATHAI, INC.: COMPANY OVERVIEW
  • TABLE 259 PATHAI, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 260 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-OCTOBER 2024
  • TABLE 261 PATHAI, INC.: DEALS, JANUARY 2021-OCTOBER 2024
  • TABLE 262 TEMPUS LABS, INC.: COMPANY OVERVIEW
  • TABLE 263 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 264 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-OCTOBER 2024
  • TABLE 265 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 266 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW
  • TABLE 267 VERILY LIFE SCIENCES, LLC: COMPANY OVERVIEW
  • TABLE 268 DEEPPATH: COMPANY OVERVIEW
  • TABLE 269 4D PATH INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 5 AI IN PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION
  • FIGURE 6 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN PATHOLOGY
  • FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024-2029)
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 TOP-DOWN APPROACH
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 16 DEVELOPMENT OF CNNS AND AI LEARNING MODELS TO PROPEL MARKET
  • FIGURE 17 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 19 US TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF HEALTH AND HUMAN SERVICES (SEPTEMBER 2024)
  • FIGURE 22 AI IN PATHOLOGY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 23 ECOSYSTEM ANALYSIS
  • FIGURE 24 VALUE CHAIN ANALYSIS
  • FIGURE 25 EUROPE: IVDR TIMELINE
  • FIGURE 26 THERE IS MODERATE-TO-HIGH COMPETITIVE INTENSITY AMONG MARKET PLAYERS
  • FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2015-OCTOBER 2024
  • FIGURE 28 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN PATHOLOGY PATENTS (JANUARY 2015 TO MAY 2024)
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN PATHOLOGY PRODUCTS
  • FIGURE 30 KEY BUYING CRITERIA FOR AI IN PATHOLOGY PRODUCTS
  • FIGURE 31 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET
  • FIGURE 32 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY
  • FIGURE 33 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT
  • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS FOR AI IN PATHOLOGY MARKET, 2019-2023
  • FIGURE 36 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2023)
  • FIGURE 37 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 38 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 39 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF LIFE SCIENCE ANALYTICS VENDORS
  • FIGURE 41 EV/EBITDA OF KEY VENDORS
  • FIGURE 42 AI IN PATHOLOGY MARKET: BRAND/PRODUCT COMPARISON ANALYSIS
  • FIGURE 43 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 45 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 47 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2023)